

論文等 (2022 年 1 月-2022 年 12 月)

- **Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013**
Hironaka S, Sadachi R, Machida N, Iwasa S, Yamada Y, Sasako M, Yoshikawa T, Boku N, Terashima M
Jpn J Clin Oncol. 2022 Jan 3;52(1):14-23 doi: 10.1093/jjco/hyab160 PMID: 34668562
- **Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).**
Shibuki T, Mizuta T, Shimokawa M, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Mitsugi K, Nio K, Ide Y, Ureshino N, Shirakawa T, Otsuka T.
BMC Cancer 2022 Jan 3;22(1):19 doi:10.1186/s12885-021-09139-y PMID: 34980029
- **Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)**
Koga F, Kawaguchi Y, Shimokawa M, Murayama K, Nakashita S, Oza N, Ureshino N, Takahashi H, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Shirakawa T, Otsuka T, Mitsugi K.
J Geriatr Oncol 2022 Jan;13(1):82-87 doi: 10.1016/j.jgo.2021.06.011 PMID: 34215525 Epub 2021 Jun 29
- **Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study**
Komatsu Y, Hironaka S, Tanizawa Y, Cai Z, Piao Y, Boku N
Adv Ther. 2022 Jan;39(1):296-313 doi: 10.1007/s12325-021-01931-3 PMID: 34716560 Epub 2021 Oct 29
- **A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC.**
Daichi Fujimoto, Satoru Miura, Kenichi Yoshimura, Kazushige Wakuda, Yuko Oya, Koji Haratani, Shoichi Itoh, Takehiro Uemura, Ryotaro Morinaga, Takayuki Takahama, Kazuhisa Nakashima, Motoko Tachihara, Go Saito, Junko Tanizaki, Kohei Otsubo, Satoshi Ikeda, Hirotaka Matsumoto, Satoshi Hara, Akito Hata, Takeshi Masuda, Nobuyuki Yamamoto
JTO Clin Res Rep. 2021 Dec 16;3(2):100265. doi: 10.1016/j.jtocrr.2021.100265. eCollection 2022 Feb. PMID: 35146460
- **Phase I study of weekly nab paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non small cell lung cancer.**
S Omori, H Harada, K Mori, Y Hisamatsu, Y Tsuboguchi, H Yoshioka, R Morinaga, H Daga, T Kurata, T Takahashi
Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w PMID: 34495421 Epub 2021 Sep 8
- **Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1**
Oshima K, Kato K, Ito Y, Daiko H, Nozaki I, Nakagawa S, Shibuya Y, Kojima T, Toh Y, Okada M, Hironaka S, Akiyama Y, Komatsu Y, Maejima K, Nakagawa H, Onuki R, Nagai M, Kato M, Kanato K, Kuchiba A, Nakamura K, Kitagawa Y
Cancer Sci. 2022 Mar;113(3):1018-1027 doi: 10.1111/cas.15251 PMID: 34962019 Epub 2022 Jan 10

- **Histologic transformation of epidermal growth factor receptor–mutated lung cancer.**
Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, Kazushige Wakuda, Yuki Sato, Yoshitaka Kawa, Toshihide Yokoyama, Motohiro Tamiya, Ryota Hiraoka, Naoki Shingu, Hideki Ikeda, Akihiro Tamiya, Masaki Kanazu, Eisaku Miyauchi, Satoru Miura, Masaaki Yanai, Makiko Yomota, Ryotaro Morinaga, Takashi Yokoi, Akito Hata, Hidekazu Suzuki, Hirotaka Matsumoto, Shinya Sakata, Naoki Furuya, Yuhei Harutani, Ichiro Nakachi, Ayumu Otsuki, Shinya Uematsu, Satoshi Hara, Keiki Yokoo, Takeya Sugimoto, Nobuyuki Yamamoto
Eur J Cancer. 2022 May;166:41-50. doi: 10.1016/j.ejca.2022.02.006 PMID: 35278824 Epub 2022 Mar 9
- **Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study**
Mori Y, Kikuchi O, Horimatsu T, Hara H, Hironaka S, Kojima T, Kato K, Tsushima T, Ishihara R, Mukai K, Uozumi R, Tada H, Kasai H, Kawaguchi A, Muto M
Esophagus. 2022 Jul;19(3):444-451 doi: 10.1007/s10388-021-00905-2 PMID: 35050435 Epub 2022 Jan 20
- **Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).**
Tanzawa S, Makiguchi T, Tasaka S, Inaba M, Ochiai R, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Miyamoto Y, Yokoyama T, Matsumoto C, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Seki N.
Ther Adv Med Oncol.
2022 Jul 29;14:17588359221116603 doi: 10.1177/17588359221116603. eCollection 2022. PMID: 35923924
- **Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicentre**
Ito T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T, Sugimoto N, Ojima H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Saruta M, Otsu S, Shinozaki K, Fujiwara T, Tamura T, Baba E, Shiozawa M, Denda T, Ueno H, Nagashima K, Shimada Y.
Int J Clin Oncol 2022 Sep;27(9):1450-1458. doi: 10.1007/s10147-022-02208-7 PMID: 35861943 Epub 2022 Jul 21
- **Multicenter retrospective analysis of original versus modified FOLFIRINOX in metastatic pancreatic cancer: Results of the NAPOLEON study.**
Nakazawa J, Tsuruta N, Shimokawa M, Kawahira M, Arima S, Ido A, Koga F, Ueda Y, Komori A, Otsu S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Otsuka T, Shirakawa T, Mitsugi K.
Oncology 2022 Oct 4. 10.1159/000527176. Online ahead of print.
- **Enhanced phosphorylation of c-Jun by cisplatin treatment as a potential predictive biomarker for cisplatin response in combination with patient-derived tumor organoids.**
Tsukamoto Y, Kurogi S, Shibata T, Suzuki K, Hirashita Y, Fumoto S, Yano S, Yanagihara K, Nakada C, Mieno F, Kinoshita K, Fuchino T, Mizukami K, Ueda Y, Etoh T, Uchida T, Hanada T, Takekawa M, Daa T, Shirao K, Hironaka S, Murakami K, Inomata M, Hijiya N, Moriyama M
Lab Invest. 2022 Dec;102(12):1355-1366 doi: 10.1038/s41374-022-00827-2. PMID: 35922477 Epub 2022 Aug 3

- **A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site.**

Nishikawa K, Hironaka S, Inagaki T, Komori A, Otsu S, Mitsugi K, Makiyama A, Watanabe K, Tamura S, Okumura Y, Kusaba H, Esaki T, Baba E, Shirao K.

Jpn J Clin Oncol 2022 Dec 5;52(12):1416-1422. doi: 10.1093/jjco/hyac143 PMID: 36047806

- **A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.**

Tanaka H, Tanzawa S, Misumi T, Makiguchi T, Inaba M, Honda T, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Fukuda Y, Yasugi M, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Shiraishi K, Matsutani N, Seki N.

Ther Adv Med Oncol.

2022 Dec 18;14:17588359221142786 doi: 10.1177/17588359221142786 eCollection 2022. PMID: 36570411